Skip to main content

Table 3 Predictors of LUNDEX-corrected EULAR good response. Odds ratios (95% confidence intervals)

From: Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register

  6 months 12 months
Univariate Multivariate Univariate Multivariate
Male sex 2.11 (1.41–3.13) 2.28 (1.45–3.57) 2.46 (1.71–3.54) 2.14 (1.44–3.19)
≥ 2 bDMARDs Reference (1.0) Reference (1.0) Reference (1.0) Reference (1.0)
Bionaïve 4.00 (2.60–6.15) 3.59 (2.25–5.72) 4.45 (2.95–6.71) 4.29 (2.77–6.65)
1 bDMARD 1.11 (0.72–1.72) * 1.11 (0.74–1.69) **
DAS28-CRP (per SD) at baseline 0.95 (0.80–1.14) * 0.98 (0.83–1.16) **
DAS28 (per unit) at baseline 0.91 (0.79–1.04) * 0.97 (0.85–1.10) **
VAS pain (per SD) at baseline 0.96 (0.80–1.15) * 0.89 (0.75–1.06) **
Methotrexate at baseline 1.36 (0.95–1.94) * 1.46 (1.04–2.06) **
HAQ score (per SD) at baseline 0.64 (0.52–0.77) 0.75 (0.61–0.93) 0.65 (0.54–0.78) 0.74 (0.61–0.90)
Disease duration (per SD) at baseline 0.79 (0.65–0.96) * 0.72 (0.59–0.87) **
Age (per SD) at baseline 0.76 (0.65–0.91) 0.79 (0.65–0.96) 0.97 (0.82–1.14) **
Glucocorticoids at baseline 0.59 (0.42–0.83) 0.59 (0.40–0.86) 0.72 (0.52–1.00) **
csDMARD at baseline 1.40 (0.96–2.06) * 1.25 (0.87–1.79) **
s.c. abatacept administration Reference (1.0) * Reference (1.0) **
i.v. abatacept administration 0.53 (0.38–0.75) * 0.70 (0.51–0.98) **
  1. *Not included in the final model. The first multivariate model in the stepwise analysis included sex, bDMARD exposure, DAS28, methotrexate at baseline, HAQ-DI, disease duration, age, glucocorticoids at baseline, csDMARDs at baseline, and route of abatacept administration. **Not included in the final model. The first multivariate model in the stepwise analysis included sex, bDMARD exposure, methotrexate at baseline, HAQ-DI, disease duration, glucocorticoids at baseline, and route of abatacept administration. Multivariate model includes 754 patients at 6 months, 829 patients at 12 months